Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Jan 30;9(21):15792-15815.
doi: 10.18632/oncotarget.24353. eCollection 2018 Mar 20.

Value-based genomics

Jun Gong  1 , Kathy Pan  2 , Marwan Fakih  1 , Sumanta Pal  1 , Ravi Salgia  3
Affiliations
Review

Value-based genomics

Jun Gong et al. Oncotarget. .

Abstract

Advancements in next-generation sequencing have greatly enhanced the development of biomarker-driven cancer therapies. The affordability and availability of next-generation sequencers have allowed for the commercialization of next-generation sequencing platforms that have found widespread use for clinical-decision making and research purposes. Despite the greater availability of tumor molecular profiling by next-generation sequencing at our doorsteps, the achievement of value-based care, or improving patient outcomes while reducing overall costs or risks, in the era of precision oncology remains a looming challenge. In this review, we highlight available data through a pre-established and conceptualized framework for evaluating value-based medicine to assess the cost (efficiency), clinical benefit (effectiveness), and toxicity (safety) of genomic profiling in cancer care. We also provide perspectives on future directions of next-generation sequencing from targeted panels to whole-exome or whole-genome sequencing and describe potential strategies needed to attain value-based genomics.

Keywords: cost-effectiveness; next-generation sequencing; pathways; precision oncology; value-based care.

PubMed Disclaimer

Conflict of interest statement

CONFLICTS OF INTEREST All authors declare no potential conflicts of interest.

References

    1. National Research Council . Toward precision medicine: building a knowledge network for biomedical research and a new taxonomy of disease. Washington, DC: The National Academies Press; 2011. https://doi.org/10.17226/13284. - DOI - PubMed
    1. Collins FS, Varmus H. A new initiative on precision medicine. N Engl J Med. 2015;372:793–795. - PMC - PubMed
    1. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, Vogel V, Robidoux A, Dimitrov N, Atkins J, Daly M, Wieand S, Tan-Chiu E, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 1998;90:1371–1388. - PubMed
    1. Fisher B, Jeong JH, Bryant J, Anderson S, Dignam J, Fisher ER, Wolmark N, National Surgical Adjuvant Breast and Bowel Project randomised clinical trials Treatment of lymph-node-negative, oestrogen-receptor-positive breast cancer: long-term findings from National Surgical Adjuvant Breast and Bowel Project randomised clinical trials. Lancet. 2004;364:858–868. - PubMed
    1. Jordan VC. Tamoxifen as the first targeted long-term adjuvant therapy for breast cancer. Endocr Relat Cancer. 2014;21:R235–R246. - PMC - PubMed